EAM
MIRM icon

Eventide Asset Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Eventide Asset Management’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$130M Sell
1,408,871
-684,711
-33% -$64.4M 2.15% 4
2025
Q4 		$165M Sell
2,093,582
-428,981
-17% -$30.8M 2.58% 3
2025
Q3 		$185M Sell
2,522,563
-114,922
-4% -$7.31M 3.04% 2
2025
Q2 		$134M Buy
2,637,485
+110,485
+4% +$4.92M 2.35% 4
2025
Q1 		$114M Sell
2,527,000
-79,938
-3% -$3.77M 2.27% 4
2024
Q4 		$108M Sell
2,606,938
-838,425
-24% -$34.9M 1.96% 6
2024
Q3 		$134M Sell
3,445,363
-169,457
-5% -$6.76M 2.32% 6
2024
Q2 		$124M Buy
3,614,820
+314,420
+10% +$8.24M 2.12% 8
2024
Q1 		$82.9M Buy
3,300,400
+636,751
+24% +$17.5M 1.3% 25
2023
Q4 		$78.6M Sell
2,663,649
-1,294,930
-33% -$39.2M 1.28% 27
2023
Q3 		$125M Buy
3,958,579
+499,378
+14% +$13.7M 2.25% 7
2023
Q2 		$89.5M Buy
3,459,201
+1,400,000
+68% +$37.2M 1.51% 18
2023
Q1 		$49.5M Buy
2,059,201
+2,201
+0.1% +$50.2K 0.91% 37
2022
Q4 		$40.1M Buy
2,057,000
+782,000
+61% +$15.5M 0.79% 44
2022
Q3 		$26.8M Buy
+1,275,000
New +$30.7M 0.53% 62

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Eventide Asset Management's MIRM Position: Q1 2026 in Review

Eventide Asset Management reduced its Mirum Pharmaceuticals (MIRM) stake by 33% in Q1 2026, selling an estimated $64.4M and leaving 1,408,871 shares worth $130M. The position accounts for 2.15% of the portfolio, ranked #4.

Eventide Asset Management first reported a position in MIRM in Q3 2022 and has held it in 15 quarters since. The position peaked at $185M in Q3 2025. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • Eventide Asset Management held 1,408,871 shares of Mirum Pharmaceuticals worth $130M as of Q1 2026.
  • Eventide Asset Management sold 684,711 Mirum Pharmaceuticals shares in Q1 2026, an estimated $64.4M.
  • Mirum Pharmaceuticals made up 2.15% of Eventide Asset Management's portfolio in Q1 2026, its #4 holding.
  • Eventide Asset Management first reported a position in Mirum Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
  • Eventide Asset Management's Mirum Pharmaceuticals position peaked at $185M in Q3 2025.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Eventide Asset Management's 13F filing for Q1 2026, filed 15 May 2026.